Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape

Phase III Data Seen As Underwhelming

Executive Summary

The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption

You may also be interested in...

After CRL In MDD, Sage/Biogen’s Zuranolone Would Need More Effectiveness Data

Zurzuvae becomes first oral drug for postpartum depression but will need at least one additional study to enter larger major depressive disorder market after US FDA cites a lack of effectiveness. Continued MDD development in doubt with both Sage and partner Biogen in cost-cutting frame.

Reprioritization On Cards After Sage/Biogen’s Zurzuvae Receives CRL For MDD

The firms’ Zurzuvae has become the first oral drug to win US approval for postpartum depression but a thumbs down in the larger major depressive disorder indication has raised concerns that Biogen could pull out of the partnership as Sage turns its efforts to cutting costs.

Praxis Moves Away From Depression With Surprising Phase II/III Failure

With GABA-A modulator PRAX-114 missing all endpoints in a monotherapy study, Praxis will cease development of that drug and focus on its candidates for essential tremor and epilepsy.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts